Nurexone Biologic Inc · TSXV:NRX
Nurexone Biologic — Investor Presentation (September 2022)
21 slides from Nurexone Biologic's investor presentation, September 2022
Slide 1: From Spinal Cord Injury to Functional Recovery
FROM SPINAL CORD INJURY TO FUNCTIONAL RECOVERY NurExone Biologic Inc. TSXV: NRX FSE: J90
Slide 2: Disclaimer
DISCLAIMER: Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction. This presentation contains “forward-looking information” for purposes of applicable securities laws
Slide 3: Spinal Cord Injuries
SPINAL CORD INJURIES Life-altering and an economical burden ● Between 250 000 and 500 000 people suffer a spinal cord injury (SCI) around the world every year. The majority of spinal cord injuries are due to road traffic crashes, falls or violence. ● SCI may impact mobility and induce paralysis, pat
Slide 4: Estimated lifetime costs per patient with spinal cord injuries in the U.S. (2021)
Estimated lifetime costs/patient with spinal cord injuries in the U.S. (2021) Source: Statista 2022 Confidential & proprietary | 4
Slide 5: Our Mission
OUR MISSION: TO DEVELOP A NOVEL, BIOLOGICAL AND MINIMALLY INVASIVE TREATMENT FOR SPINAL CORD INJURIES (SCI) AND OTHER CENTRAL NERVOUS SYSTEM (CNS) INDICATIONS Confidential & proprietary | 5
Slide 6: NurExone's Bio-Guided ExoTherapy
NUREXONE’S BIO-GUIDED EXOTHERAPY Confidential & proprietary | 6
Slide 7: What Is ExoTherapy?
WHAT IS EXOTHERAPY? MSC derived EV + Modified siRNA = Nurexone’s Proprietary loaded EV 1. Exosomes 2. Therapeutic Compounds 3. ExoTherapy Exosomes are biologically-guided Promotes the biochemical environment that ExoTherapy is produced by nanocarriers that are capable of induces a healing process. N
Slide 8: ExoTherapy: Delivery and Healing
EXOTHERAPY: Delivery and Healing Functional Recovery Patient Delivery ● Nurexone’s first ExoTherapy is ExoPTEN for spinal cord injuries ExoTherapy is non-invasive and designed to ● In preclinical animal studies with a fully transected be inhaled by patients. The nano-size of the exosomes enables the
Slide 9: NurExone Preclinical Study
NUREXONE PRECLINICAL STUDY Overview ● Full spinal cord transection and intranasal administration of the ExoPTEN ● Biologically guided to injured tissue ● Nurexone’s ExoTherapy led to significant motor improvement, sensory recovery, and faster urinary reflex Spinal cord injury ● Functional recovery w
Slide 10: Neural Functional Recovery
NEURAL FUNCTIONAL RECOVERY MRI IMAGING OF MICE SPINAL CORD TIMING POST 56 DAYS Beginning of experiment Full functionality Following the complete transection of the spinal Full paralysis cord Exosome only (control) None Intranasal Exo-PTEN administration – synergistic Restored between control group f
Slide 11: ExoTherapy Summary
EXOTHERAPY SUMMARY HOLDS GREAT PROMISE FOR CLINICAL HEALING FEATURES: • NON-INVASIVE • RAPID • CELL-FREE • Biologically-guided • No immune response in patients • Off the shelf administration Confidential & proprietary | 11
Slide 12: Competition - Comparison
COMPETITION - Comparison Internasal Epidural Autologous Allogeneic ExoPTEN Electrical Stem Cell Stem Cell Technology Stimulation Potential to repair full transection Immune evasion Off the shelf use Non invasive Confidential & proprietary | 12
Slide 13: Growing Industry
GROWING INDUSTRY Exosomes as the future of drug delivery CODIAK PURETECH EVOX EVOX BIOSCIENCE $1B deal Up to $1B $800M $1.2B Exosome licensed to Exosome Deal with Eli Lilly Roche. tech licensed Tekada collaboration to Jazz. Roche licensed Jazz licensed Codiak Takeda and Evox Eli Lilly and Evox $1.2
Slide 14: Our Expanding IP Portfolio
OUR EXPANDING IP PORTFOLIO ● Intranasal ExoPTEN (PCT) ● 2 PCTs – on Production and Composition of Matter of our exosomes ● 3 provisionals on loading technique and siRNA target sequences Confidential & proprietary | 14
Slide 15: Road Map
ROAD MAP Q2 2022 Q3 2022 Q4 2022 H2 2022 Q1 2023 H1 2023 H2 2023 Filling new Finalize Establish scaled INTERACT Opening in- In-Vivo experiments IND submission patents product up ExoPTEN meeting with house scale for IND submission characterization Production the FDA R&D facility The information prese
Slide 16: Summary
SUMMARY ● Founded in 2020, by Prof. Shulamit Levenberg from the Haifa Technion and Prof. Daniel Offen from the Tel Aviv University, together with serial entrepreneur Yoram Drucker ● Bio-guided Exotherapy based on exosomes loaded with specialized compounds to treat acute spinal cord injuries ● Produc
Slide 17: Our Team
OUR TEAM Lior Shaltiel, PhD Chief Executive Officer Business Development Finance Scientific Development Scientific Research Communications Yoram Drucker Lyora Aharonov, PhD Shulamit Inbar Paz Benayoun, Eran Ovadya, MBA z Vice President Research & Development Levenberg, PhD LLB Strategic Development
Slide 18: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Prof. Gabriel Zeilig, MD Prof. Michael Belkin Prof. Shulamit Levenberg Prof. Daniel Offen Prof. Nahshon Knoller, MD Scientific Advisory Board Scientific Advisory Board Scientific Advisory Board Prof. Gabi Zeilig is the Prof. Belkin was the founder director of the Department
Slide 19: Directors
DIRECTORS ISRAEL CANADA Ron Mayron Eyal Flom Dr. Lior Shaltiel Yoram Drucker Oded Orgil, LL.B. James (Jay) Richardson Director Director CEO Founder & VP Business Development Mr. Orgil has over 25 years Mr. Richardson has served as Mr. Mayron held Mr. Flom has served as An entrepreneur and experience
Slide 20: Share Structure
TSXV: NRX Share Structure September 14, 2022 Share Price C$0.43 Market Capitalization C$18.23 million Common Shares 42,383,963 Warrants1 15,223,806 Options2 4,151,995 Fully Diluted Share Capital 61,759,764 Cash3 US$4.02 million Insider Ownership ∼11% 1. Exercise Price: $1.20 CAD; expires between Jun
Slide 21: Thank You
TSXV: NRX THANK YOU For more information please contact: Dr Lior Shaltiel, CEO: + 972 52 4803034 eMail: lior@nurexone.com Yoram Drucker, VP Strategic Operations: + 972 54 4711171 eMail: yoram@nurexone.com Investor Relations: +1 905 347 5569 eMail: IR@nurexone.com DISCLOSURE The matters discussed in
NurExone Biologic — Investor Presentation (September 2022) on 6ix